|
Dr. DePaoli joins InteKrin after more than 16 years of experience in the diabetes and obesity field. He trained in Clinical and Molecular Endocrinology at the University of Chicago with Dr. Kenneth Polonski and in the laboratory of Dr. Graham Bell. His clinical and research interests in diabetes and obesity were focused during his work at the Sansum Diabetes Research Institute with Dr. Lois Jovanovich, which led him to join Amgen to develop a Metabolic Disease Area. His work at Amgen has been pivotal in enabling multiple clinical applications of Leptin. Dr. DePaoli has gone on to work on a broad array of cardio-metabolic disease targets with a focus on translating novel pathways into the clinic. These pathways include: 11 Beta HSD-1, Myostatin, RANK Ligand, IL-1 receptor, Calcium Sensing Receptor, PPAR-gamma modulation, DPP-4, and MCH-R1. His accomplishments at Amgen that will bring value to InteKrin include extensive involvement in the Business Development activities, including in-licensing (Biovitrum), out-licensing (Amylin and InteKrin), and acquisitions (Tularik and Alantos). | 